Citius Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Dec 23, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Dec 23, 2025
CTXR$0.49-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
| Preferred · Common Stock · Additional Paid-In · Accumulated · Total Citius Pharmaceuticals, Inc. Stockholders’ · Non-Controlling · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Stock | Shares | Amount | Capital | Deficit | Equity | Interest | Equity | |
| Balance, September 30, 2023 | — | 6,354,371 | $6,354 | $253,056,133 | $(162,231,379) | $90,831,108 | $600,380 | $91,431,488 |
| Issuance of common stock for services | — | 15,479 | 15 | 284,161 | — | 284,176 | — | 284,176 |
| Issuance of common stock upon exercise of stock options | — | 2,082 | 2 | (2) | — | — | — | — |
| Sale of common stock, net of costs | — | 875,311 | 876 | 13,802,808 | — | 13,803,684 | — | 13,803,684 |
| Stock-based compensation expense | — | — | — | 11,839,678 | — | 11,839,678 | — | 11,839,678 |
| Merger, net of transaction costs of $2,358,780 | — | — | — | (3,831,357) | — | (3,831,357) | — | (3,831,357) |
| Minority interest from Merger | — | — | — | (3,711,000) | — | (3,711,000) | 3,711,000 | — |
| Net loss | — | — | — | — | (39,425,839) | (39,425,839) | — | (39,425,839) |
| Net loss attributable to noncontrolling interest | — | — | — | — | 287,000 | 287,000 | (287,000) | — |
| Balance, September 30, 2024 | — | 7,247,243 | 7,247 | 271,440,421 | (201,370,218) | 70,077,450 | 4,024,380 | 74,101,830 |
| November 2024 sale of common stock, net of costs of $425,949 | — | 480,000 | 480 | 2,573,571 | — | 2,574,051 | — | 2,574,051 |
| January 2025 sale of common stock, net of costs of $342,833 | — | 743,496 | 744 | 2,656,423 | — | 2,657,167 | — | 2,657,167 |
| April 2025 sale of common stock and pre-funded warrants, net of costs of $256,116 | — | 465,000 | 465 | 1,743,292 | — | 1,743,757 | — | 1,743,757 |
| June 2025 sale of common stock and pre-funded warrants, net of costs of $571,126 | — | 540,000 | 540 | 5,430,296 | — | 5,430,836 | — | 5,430,836 |
| July 2025 sale of common stock by Citius Oncology, net of costs of $1,453,012 | — | — | — | 3,770,278 | — | 3,770,278 | (3,776,710) | 7,546,988 |
| September 2025 sale of common stock by Citius Oncology, net of costs of $1,380,146 | — | — | — | 4,090,493 | — | 4,090,493 | (3,529,361) | 7,619,854 |
| Issuance of common stock for services | — | 20,000 | 20 | 26,580 | — | 26,600 | — | 26,600 |
| Issuance of common stock upon exercise of pre-funded warrants | — | 5,654,131 | 5,654 | (5,088) | — | 566 | — | 566 |
| Sales of common stock under at the market offering agreement, net of costs | — | 2,917,874 | 2,918 | 4,727,011 | — | 4,729,929 | — | 4,729,929 |
| Sale of Series A preferred stock | 1 | — | — | 100 | — | 100 | — | 100 |
| Redemption of Series A preferred stock | (1) | — | — | (100) | — | (100) | — | (100) |
| Stock-based compensation expense | — | — | — | 9,882,962 | — | 9,882,962 | 953,329 | 10,836,291 |
| Net loss | — | — | — | — | (39,740,269) | (39,740,269) | — | (39,740,269) |
| Net loss attributable to noncontrolling interest | — | — | — | — | 2,306,358 | 2,306,358 | (2,306,358) | — |
| Balance, September 30, 2025 | — | 18,067,744 | $18,068 | $306,336,239 | $(238,804,129) | $67,550,178 | $9,977,422 | $77,527,600 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.